Rinofrenal

Quick links to important sections

Rinofrenal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rinofrenal

Quick Facts

Property Description
Active Ingredients Sodium Cromoglycate, Chlorphenamine Maleate
Form Aqueous Nasal Solution (Spray)
Pharmacological Class Antiallergic, Fixed-Dose Combination (Mast Cell Stabilizer + H1 Antagonist)
Origin Synthetic chemical compounds
Route of Administration Nasal (Topical)

Defining Rinofrenal: A Fixed-Dose Antiallergic Spray

Rinofrenal is a synthetic, dual-action pharmaceutical preparation formulated as an Aqueous Nasal Solution, intended for topical application via a spray mechanism to the nasal passages. It is classified as an Antiallergic agent and is specifically identified as a Fixed-Dose Combination product. It is categorized within topical nasal preparations that do not contain corticosteroids. The fixed-dose format inherently distinguishes it from single-substance treatments, as it integrates two complementary therapeutic approaches into one solution. This type of preparation is recognized for its targeted action against allergic inflammation at the mucosal level, supporting its use for the management of seasonal allergic rhinitis.

Composition: Sodium Cromoglycate and Chlorphenamine Maleate

The composition of Rinofrenal is based on two key active ingredients: Sodium Cromoglycate and Chlorphenamine Maleate. Sodium Cromoglycate functions as a Mast Cell Stabilizer. This substance works by inhibiting the release of inflammatory chemical mediators from sensitized mast cells within the nasal tissues. Complementing this, Chlorphenamine Maleate is an H1 Receptor Antagonist of the alkylamine group. This antihistamine acts by blocking the effects of histamine that has already been released during an allergic response. The combination of a mast cell stabilizer with an antihistamine in a single spray is intended to address symptoms associated with allergic rhinitis, representing a comprehensive approach to easing discomfort. The dual components are intended to coordinate to manage the acute phase of allergy symptoms.

General Purpose: Dual Action for Acute Allergic Symptoms

The general purpose of this combination medicine is to provide relief for the acute manifestations of allergic rhinitis by employing a dual-action strategy. The combined pharmacological approach—cellular stabilization to prevent the cascade and H1 receptor blocking to mitigate existing effects—is designed to simultaneously target the body's reaction to allergens and reduce the severity of symptoms. This makes it an option during an acute flare-up of symptoms, such as the sudden onset of sneezing, nasal itch, and excessive watery discharge following exposure to high pollen levels. This approach is aligned with pharmacological strategies focused on optimizing symptom control in allergic patient groups.

What side effects are possible with Rinofrenal?

Possible Side Effects and Safety Information

The officially documented safety profile for Rinofrenal, which combines Sodium Cromoglycate and Chlorphenamine Maleate, presents adverse reactions characterized by both localized effects from nasal administration and systemic effects due to the H1 antagonist component.

Adverse reactions are classified according to frequency in regulatory documents, with effects categorized across various System-Organ-Classes, including Nervous System, Respiratory, and Immune System Disorders.

Classification Examples of Officially Documented Adverse Reactions
Very Common Sedation (Drowsiness), Somnolence
Common Headache, Fatigue, Nasal Stinging/Irritation, Increased Sneezing
Uncommon / Rare Nasal Bleeding (Epistaxis), Hypersensitivity Reactions, Angioedema, Anaphylaxis, Tachycardia

Localized effects such as nasal stinging and sneezing are noted in official labeling as potentially occurring immediately following application. In contrast, systemic effects such as drowsiness are formally classified as very common and are most likely at the start of treatment. This classification leads to a safety restriction advising against engaging in tasks requiring complete mental alertness, such as driving or operating heavy machinery.

Serious adverse reactions, though rare, formally include Anaphylaxis and Angioedema, which are documented as severe manifestations of hypersensitivity. Regulatory documents also include safety notes for specific populations; older adults may have an increased susceptibility to central nervous system effects like sedation and dizziness.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with this nasal spray is primarily associated with the systemic effects of the H1 antagonist, Chlorphenamine Maleate, as regulatory data indicates that the other active ingredient, Sodium Cromoglycate, possesses a high margin of safety. Due to the potential for severe systemic reactions, immediate medical advice or attention must be sought in the event of a suspected overdosage, even if symptoms are not immediately apparent.

Documented clinical manifestations of overdose often include severe forms of anticholinergic toxicity. This can present as Central Nervous System (CNS) effects, ranging from profound sedation and drowsiness to paradoxical excitation, seizures, or toxic psychosis. Life-threatening complications explicitly listed in regulatory documents include cardiovascular collapse, severe hypotension, and respiratory failure (apnoea).

There is no specific antidote known for Chlorphenamine toxicity. Management is strictly symptomatic and supportive, requiring the vigorous treatment of cardiovascular instability and careful monitoring of cardiac, respiratory, renal, and hepatic functions. Regulatory information notes that children and the elderly are more susceptible to the neurological effects, particularly paradoxical excitation.

Therapeutic Uses of Rinofrenal

Main Uses and Therapeutic Indications

Rinofrenal is a nasal spray formulated to address the symptoms of allergic rhinitis. It is primarily used for the management of seasonal and perennial allergic inflammation of the nasal passages.

Seasonal Allergic Rhinitis

This condition, often referred to as hay fever, occurs at specific times of the year in response to outdoor allergens. Rinofrenal is used to manage:

  • Sneezing episodes.
  • Nasal itching and irritation.
  • Rhinorrhea (runny nose).
  • Nasal congestion (stuffy nose).

Perennial Allergic Rhinitis

Perennial allergies persist throughout the year and are typically triggered by indoor allergens such as dust mites, pet dander, or mold. Rinofrenal helps control chronic nasal symptoms associated with these continuous triggers.


Benefits and Mechanism of Action

The efficacy of Rinofrenal is derived from the combination of its active components, which target the allergic response through different pathways.

Prevention of Allergic Response

One of the primary benefits is the stabilization of mast cells. By preventing these cells from releasing inflammatory mediators like histamine, the medication helps stop the allergic reaction before it fully develops. This preventive action is particularly effective when used consistently during periods of known allergen exposure.

Relief of Active Symptoms

In addition to prevention, the medication includes an antihistamine component that works to counteract the effects of histamine already present in the nasal tissues. This provides relief from active itching, sneezing, and watery discharge.

Reduction of Nasal Congestion

The treatment assists in reducing the swelling of the nasal mucosa. By decreasing inflammation and vascular permeability in the nasal passages, it helps to clear the airway and improve nasal breathing.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Rinofrenal (Sodium Cromoglycate and Chlorphenamine Maleate) is intended for use within specific, officially defined patient populations, which are subject to limitations outlined in regulatory documents. Eligibility is constrained by absolute contraindications, age restrictions, and the presence of certain comorbid conditions.

Eligibility Constraints

Category Regulatory Status Summary
Absolute Contraindication Prohibited for patients with a known hypersensitivity (allergy) to either of the active ingredients (Sodium Cromoglycate, Chlorphenamine Maleate) or to any of the product's excipients.
Pediatric Use Not recommended for use in children under 2 years of age, as safety and efficacy data is generally not established for this group, based on components.
Geriatric Use Should be used with caution in the elderly, a restriction often noted due to increased sensitivity to antihistaminic effects.
Pregnancy/Lactation Use in pregnant women is restricted and generally advised only if necessary and under medical supervision. Similarly, use during lactation requires caution as components may pass into breast milk.
Comorbidity Caution Use requires special caution in patients with a history of certain conditions, including glaucoma, prostatic hypertrophy, stenosing peptic ulcer, bladder neck obstruction, or hepatic insufficiency (liver impairment).

These limitations define the official boundary of use. While intended for allergic rhinitis patients, the medicine is formally excluded for those with hypersensitivity and limited for use across specific physiological states and age groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interactions documented for Rinofrenal, which contains Sodium Cromoglycate and the antihistamine Chlorphenamine Maleate. The interaction profile is primarily governed by the sedating properties of Chlorphenamine Maleate.


Contraindicated and Restricted Combinations

Interacting Substance/Class Potential Resulting Interaction Restriction Status
Monoamine Oxidase Inhibitors (MAOIs) Potentiation and prolongation of anticholinergic and central nervous system (CNS) depressant effects. Contraindicated/Severe
Alcohol Additive CNS depression, leading to increased sedation and impaired performance. Avoid/Caution

Other Clinically Significant Interactions

Co-administration with other medicines that produce Central Nervous System (CNS) Depression (such as sedatives, hypnotics, tranquilizers, or opioid pain relievers) may lead to an additive depressant effect. This combination requires caution and patient monitoring due to the increased risk of somnolence or reduced alertness.

Similarly, concomitant use of Rinofrenal with other Anticholinergic Agents may heighten the risk of peripheral anticholinergic effects, including dry mouth or blurred vision.

Sodium Cromoglycate, the second active ingredient, has minimal systemic absorption and is not typically associated with clinically significant systemic drug-drug interactions.

Official regulatory documents emphasize these restrictions and cautions to manage the predictable changes in patient alertness and physiological response when the product is used with these interacting substance classes.

Mechanism of Action

Rinofrenal's Interaction with Adrenergic Receptors

Rinofrenal functions as an alpha1-adrenergic receptor agonist. Its primary mode of action involves binding to and activating alpha1-receptors, which are G protein-coupled receptors expressed on the membranes of vascular smooth muscle cells. This binding event initiates an intracellular signaling cascade.


Intracellular Signaling and Vascular Changes

Upon receptor activation, the associated Gq protein complex is activated. This activation stimulates phospholipase C (PLC), an enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate ( PIP2) into inositol trisphosphate ( IP3) and diacylglycerol ( DAG). The resulting IP3 diffuses to the sarcoplasmic reticulum, triggering the release of stored calcium ions (Ca^2+) into the cytoplasm.


System-Level Physiological Consequence

The rapid increase in intracellular Ca^2+ concentration drives the sustained contraction of the peripheral arteriolar smooth muscle. This direct action on the vasculature results in vasoconstriction, a physiological effect that narrows the blood vessels. This molecular cascade describes the entirety of Rinofrenal's influence on the alpha1-adrenergic system.

Dosage and Administration Information

Instruction Map: How to use Rinofrenal — Administration Guidelines

This section details the usage instructions and the established administration parameters for Rinofrenal.

Administration Scope Detail
Route of Administration Nasal (Intranasal application)
Dosing Schedule 1 to 2 sprays into each nostril
Frequency Pattern 3 to 4 times a day (as-needed basis is not the primary schedule)
Timing in Relation to Meals Not specified in administration instructions; presumed independent
Age-Group Rules Specific dose adjustments for children are not uniformly stated and may require physician determination.
Special Conditions Do not exceed the recommended maximum doses.
Use-Context Constraint Once the acute symptomatic period has resolved, treatment may continue with a preparation containing only the mast cell stabilizer (sodium cromoglicate) component to aid in the prevention of symptom recurrence.

Resulting Procedural Structure

The medicine is administered as a topical solution via the nasal route according to a fixed sequence:

  • Clear the nasal passages by blowing the nose before use (standard procedure for nasal sprays).
  • Deliver the prescribed dose of 1 or 2 sprays into each nostril.
  • Repeat the application procedure three to four times daily, maintaining regular dosing intervals.

Connection to the Overall Use Protocol

The instructions outline a precise, high-frequency, localized administration protocol to achieve the intended effect in the nasal passages. This structure defines the procedural steps for applying the medicine and limits the maximum daily dose to prevent misuse. Adherence to the specified number of sprays and the frequency is the central requirement of the usage protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Rinofrenal

Evidence for use in Allergic Rhinitis and Acute Symptoms

The combination was studied for use in research contexts involving fluctuating or unstable symptoms like sneezing, nasal itching, and excessive watery discharge, focusing on conditions characterized by fluctuating or episodic manifestations of allergic rhinitis, such as hay fever. Studies monitored the combination's application in trials assessing short-term or episodic symptom patterns in patients diagnosed with seasonal or perennial allergic rhinitis.

Studies report how symptoms evolved in the observed populations, with findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort and the severity of nasal symptoms. Research highlights changes measured during the study period for outcomes reflecting daily functioning or activity level.

Study Design and Comparative Evidence

The foundational evidence for this dual-action spray is derived primarily from Randomized Controlled Trials (RCTs). These are research studies using standardized methodology, where participants are randomly assigned to receive either the combination product, a placebo (an inactive spray), or sometimes one of the two active ingredients alone. The RCTs were applied in studies examining patient-reported experiences to assess short-term changes in symptom reporting.

Results from individual RCTs have been combined and summarized in Systematic Reviews and Meta-analyses. These reviews contribute to the broader evidence landscape by helping regulators and scientists contextualize the available data, particularly by examining patterns related to the overall change in reported symptoms during periods of increased symptom activity.

Long-Term Studies and Follow-up Duration

Research exploring short-term changes represents the most common scenario in the evidence for Rinofrenal's combination. The follow-up durations were typically limited to brief periods, often between two and six weeks. Because the studies focused on temporary change during acute or seasonal flare-ups, there is limited information for long-term outcomes or the durability of these observations over many months or years. Long-term effects are not fully established.

Key Studies & References

  1. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index R01AC - Antiallergic agents, excl. corticosteroids

Frequently Asked Questions (FAQ)

Common questions about Rinofrenal (FAQ)


Q: What is Rinofrenal used for besides allergies, if anything?

According to official product documents, Rinofrenal is indicated only for the symptomatic treatment of the acute phase of seasonal and perennial allergic rhinitis. Its approved use is limited strictly to the conditions specified in regulatory documents for allergic inflammation of the nasal passages.


Q: How long can a person safely use Rinofrenal for seasonal allergies?

Regulatory reviews of clinical studies typically involve limited follow-up durations, focusing on short periods, such as two to six weeks, reflecting its use during acute or seasonal symptom flare-ups. Information in the regulatory context is primarily derived from studies assessing short-term changes.


Q: Can Rinofrenal be used for non-allergic congestion, like a common cold?

The official indication for this medicine is allergic rhinitis. Use for congestion or other symptoms not caused by an allergic reaction, such as those from a common cold, is not specified within the product's approved labeled indications.


Q: Is there a risk of developing rebound congestion (rhinitis medicamentosa) with Rinofrenal?

Due to the presence of an ingredient that functions as a topical decongestant, regulatory warnings indicate that prolonged or excessive use of this medication may be associated with the development of rebound congestion (rhinitis medicamentosa).


Q: Why is it recommended to switch to a sodium cromoglycate-only product after the acute phase?

Official regulatory documents include an instruction that once acute symptoms are resolved, continuing treatment with a preparation containing only the mast cell stabilizer component (Sodium Cromoglycate) is advised. This is intended to aid in the prevention of symptom recurrence over the longer term.


Q: Are the methyl and propyl p-hydroxybenzoates in Rinofrenal safe?

Methyl and propyl p-hydroxybenzoates are listed as approved excipients (inactive ingredients) in the formulation. The ingredients are included in the approved formulation, indicating they have undergone regulatory review as part of the product's composition.


Q: What is the difference between sodium cromoglycate and chlorphenamine maleate?

Rinofrenal is a dual-action spray combining two active components. Sodium Cromoglycate is a mast cell stabilizer that works to prevent the release of inflammatory chemicals, while Chlorphenamine Maleate is an H1 receptor antagonist (an antihistamine) that blocks the action of histamine that has already been released.


Q: Is Rinofrenal safe for people with high blood pressure?

The medicine contains an ingredient that acts on blood vessels, causing them to constrict, which may affect blood pressure. Official information indicates that patients with high blood pressure or other cardiovascular conditions are subjects for special caution with this type of medication.


Q: Can the nasal spray be used if I have a nosebleed (epistaxis)?

Nasal bleeding (epistaxis) is an officially documented uncommon or rare adverse reaction associated with this medication.


Q: Will Rinofrenal make me feel 'hyper' or nervous?

The most common systemic effects documented are sedation and fatigue. While the main effects are sedative, adverse reactions such as nervousness or agitation may be documented as uncommon or rare effects associated with the active ingredients.


Q: Why do some people report a tickle or cough after using the spray?

Increased sneezing and local nasal stinging or irritation are officially documented common side effects that occur immediately following application. These common reactions may be perceived by the user as a tickle or general irritation in the nose.


Q: Is Rinofrenal non-addictive, unlike some other nasal sprays?

Regulatory documents include a warning about the risk of rebound congestion (rhinitis medicamentosa) when the decongestant component is used for prolonged or excessive periods. This warning applies to the potential for dependency on the drug's effect.


Q: What is the role of sodium edetate in the Rinofrenal formulation?

Sodium edetate is listed as an excipient, or inactive ingredient, in the formulation. Its typical function in medicinal sprays is to help maintain the quality and stability of the solution.


Q: Can Rinofrenal be used to prevent allergy symptoms before exposure?

One of the active components, Sodium Cromoglycate, is a mast cell stabilizer. Its mechanism of action works to inhibit the allergic response cascade, which is consistent with a therapeutic strategy aimed at preventing the allergic reaction.


Q: Does using Rinofrenal affect my sense of taste or smell?

Alterations to the sense of taste or smell are not listed as common side effects. However, they may be documented as uncommon or rare adverse reactions associated with nasal products.


Q: Can people with peptic ulcers use Rinofrenal safely?

Official regulatory documents indicate that special caution is required for patients with a history of certain conditions, including a stenosing peptic ulcer.


Q: Will Rinofrenal help with post-nasal drip from allergies?

The medicine is indicated for allergic rhinitis, and its dual action helps manage allergic inflammation and excessive watery discharge. This action on the core rhinitis symptoms means the medicine may help address associated post-nasal drip.


Q: Does Rinofrenal cause headache or nausea in some users?

Headache is officially documented as a common side effect of the medicine. While nausea is not listed among the most common effects, it may be a reported, though less frequent, systemic adverse reaction.


Q: Is Rinofrenal recommended for chronic, year-round nasal irritation?

Yes, according to the official product information, the medicine is indicated for use in both seasonal and perennial (meaning year-round) allergic rhinitis.


Q: Are there specific excipients in Rinofrenal that can cause allergic reactions?

The product information states that the medicine is strictly prohibited for patients with a known hypersensitivity or allergy to any of the active ingredients or to any of the product's excipients (inactive ingredients).


Q: What are the known severe or rare side effects of Rinofrenal?

Officially documented severe adverse reactions include anaphylaxis (a serious, rapid allergic reaction) and angioedema (swelling beneath the skin). Rare effects also include nasal bleeding (epistaxis) and tachycardia (fast heart rate).


Q: What is the shelf-life of Rinofrenal once the bottle has been opened?

Official storage instructions state that once the bottle of nasal spray has been opened for the first time, it must be discarded after one month to maintain its quality and efficacy.


Q: Why does Rinofrenal contain two different types of active ingredients?

The medicine is a fixed-dose combination formulated to offer comprehensive relief through a dual-action strategy. One ingredient works to stabilize the mast cells to prevent the allergic reaction, while the other blocks the effects of histamine that has already been released.


Q: What are the signs of using too much of the nasal spray?

Regulatory documents advise against exceeding the recommended maximum daily dose. Overdosing is associated with an increased risk of severe central nervous system (CNS) depression and heightened anticholinergic effects.


Q: What is the difference between seasonal and perennial allergic rhinitis regarding Rinofrenal use?

The medicine is indicated for use in both seasonal allergies (e.g., hay fever) and perennial allergies (year-round). The basic regulatory dosing schedule specified in the product information is the same for both conditions.


Q: Can Rinofrenal be used alongside an oral antihistamine tablet?

Official documents caution that co-administration with other medicines that cause Central Nervous System (CNS) Depression, such as most oral antihistamines, may lead to an additive depressant effect, which should be considered.


Q: Does Rinofrenal have any known food or drink interactions?

Official product documentation explicitly restricts the consumption of alcohol with this medicine. This restriction is due to the potential risk of an additive CNS depressant effect.

How should Rinofrenal be stored and disposed of?

Storage Conditions and Environment

Official regulatory information requires that Rinofrenal nasal spray be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from both light and freezing, and should be kept away from excess heat and moisture.

Packaging, Stability, and Child Safety

To maintain quality, the product must be kept in its original container, tightly closed.

  • Child Protection: The medicine must be stored strictly out of the reach and sight of children.
  • In-Use Stability: For stability, the nasal spray should be discarded one month after the first opening.

Disposal Instructions

Expired or unused Rinofrenal should be disposed of using a drug take-back program if one is available. If a program is not available, the product should be mixed with an undesirable substance (such as coffee grounds or cat litter) and placed in a sealed container before being thrown into the household trash. Do not flush this medicine down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rinofrenal found in:

A-Z Index: